Second-generation everolimus-eluting intracoronary stents: a comprehensive review of the clinical evidence

References

• Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 366(1), 54–63 (2012).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Kutryk MJ, Ong AT. Coronary artery stents. N. Engl. J. Med. 354(5), 483–495 (2006).
   PubMed Web of Science ®Google Scholar
• Garg S, Thirunavukarasu S, Piccolo R, Serruys PW, Windecker S. Coronary artery stents. In: The PCR-EAPCI Percutaneous Interventional Cardiovascular Medicine Textbook. Naber CK, Baumbach A, Vahanian A ( Eds). European Association of Percutaneous Cardiovascular Interventions, France (2018).
   Google Scholar
• Stefanini GG, Holmes DR Jr. Drug-eluting coronary artery stents. N. Engl. J. Med. 368(3), 254–265 (2013).
   PubMed Web of Science ®Google Scholar
• Lawton JS, Tamis-Holland JE, Bangalore S et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(3), e18–e114 (2022).
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur. Heart J. 40(2), 87–165 (2019).
   PubMed Web of Science ®Google Scholar
• iData Research. Over 2 million stents implanted per year in the US. (2021). https://idataresearch.com/stents-implanted-per-year-in-the-u-s/
   Google Scholar
• Abbott Vascular Inc. XIENCE™ family of drug eluting stents (2021). www.cardiovascular.abbott/int/en/hcp/products/percutaneous-coronary-intervention/xience-family.html
   Google Scholar
• Abbott Vascular Inc. Xience V and Xience Nano everolimus eluting coronary stent system (2016). https://vascular.eifu.abbott/en/hcp/home.html#StentandScaffoldSystem
   Google Scholar
• Abbott Vascular Inc. Xience PRIME and Xience PRIME LL everolimus eluting coronary stent system (2016). https://vascular.eifu.abbott/en/hcp/home.html#StentandScaffoldSystem
   Google Scholar
• Abbott Vascular Inc. Xience Xpedition, Xience Xpedition SV and Xience Xpedition LL everolimus eluting coronary stent system (2020). https://vascular.eifu.abbott/en/hcp/home.html#StentandScaffoldSystem
   Google Scholar
• Abbott Vascular Inc. Xience Alpine everolimus eluting coronary stent system (2021). https://vascular.eifu.abbott/en/hcp/home.html#StentandScaffoldSystem
   Google Scholar
• Abbott Vascular Inc. Xience Sierra everolimus eluting coronary stent system (2021). https://vascular.eifu.abbott/en/hcp/home.html#StentandScaffoldSystem
   Google Scholar
• Abbott Vascular Inc. Xience Skypoint everolimus eluting coronary stent system (2022). https://vascular.eifu.abbott/en/hcp/home.html#StentandScaffoldSystem
   Google Scholar
• Abbott Vascular Inc. Xience and Promus everolimus eluting coronary stent system (2008). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P070015
   Google Scholar
• Diagnostic and Interventional Cardiology. Abbott's 2.25 mm XIENCE V stent gets CE mark approval (2008). www.dicardiology.com/content/abbotts-225-mm-xience-v-stent-gets-ce-mark-approval
   Google Scholar
• Serruys PW, Ong AT, Piek JJ et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT FIRST trial. Euro Interv. 1(1), 58–65 (2005).
   Google Scholar
• Serruys PW, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Euro Interv. 2(3), 286–294 (2006).
   Google Scholar
• Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299(16), 1903–1913 (2008).
   PubMed Web of Science ®Google Scholar
• Gordon PC, Applegate RJ, Hermiller JB et al. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. Catheter Cardiovasc. Interv. 75(2), 179–186 (2010).
   PubMed Web of Science ®Google Scholar
• Saito S, Nakamura S, Fujii K et al. Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing. J. Invas. Cardiol. 24(9), 444–450 (2012).
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Newman W et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med. 362(18), 1663–1674 (2010).
   PubMed Web of Science ®Google Scholar
• Grube E, Chevalier B, Smits P et al. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. JACC Cardiovasc. Interv. 4(2), 168–175 (2011).
   PubMed Web of Science ®Google Scholar
• Wang Q, Pierson W, Sood P et al. Pharmacokinetic sub-study in the SPIRIT III randomized and controlled trial of XIENCE V everolimus eluting coronary stent system. J. Interv. Cardiol. 23(1), 26–32 (2010).
   PubMed Web of Science ®Google Scholar
• Wiemer M, Seth A, Chandra P et al. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. Am. Heart J. 156(4), 751; e751–e757 (2008).
   Web of Science ®Google Scholar
• Hofma SH, Brouwer J, Velders MA et al. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV stent vs. Cypher stent in primary PCI for acute myocardial infarction) trial. J. Am. Coll. Cardiol. 60(5), 381–387 (2012).
   PubMed Web of Science ®Google Scholar
• He Y, Wang R, Liu J et al. A randomized comparison of the healing response between the Firehawk stent and the Xience stent in patients with ST-segment elevation myocardial infarction at 6 months of follow-up (TARGET STEMI OCT China trial): an optical coherence tomography study. Front. Cardiovasc. Med. 9, 895167 (2022).
   PubMedGoogle Scholar
• Otake H, Ishida M, Nakano S et al. Comparison of MECHANISM of early and late vascular responses following treatment of ST-elevation acute myocardial infarction with two different everolimus-eluting stents: a randomized controlled trial of biodegradable versus durable polymer stents. Cardiovasc. Interv. Ther. 38(1), 75–85 (2023).
   PubMed Web of Science ®Google Scholar
• Grube E, Chevalier B, Guagliumi G et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am. Heart J. 163(5), 867–875; e861 (2012).
   PubMed Web of Science ®Google Scholar
• Stone GW, Kedhi E, Kereiakes DJ et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 124(8), 893–900 (2011).
   PubMed Web of Science ®Google Scholar
• Kaul U, Bangalore S, Seth A et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes. N. Engl. J. Med. 373(18), 1709–1719 (2015).
   PubMed Web of Science ®Google Scholar
• Morice MC, Mikhail GW, Modena MG et al. SPIRIT Women, evaluation of the safety and efficacy of the XIENCE V everolimus-eluting stent system in female patients: referral time for coronary intervention and 2-year clinical outcomes. Euro Intervent. 8(3), 325–335 (2012).
   Google Scholar
• Franzone A, Zaugg S, Piccolo R et al. A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: the SPIRIT WOMEN study. PLOS ONE 12(8), e0182632 (2017).
   PubMed Web of Science ®Google Scholar
• Seth A, Serruys PW, Lansky A et al. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. Euro Interv. 5(7), 788–794 (2010).
   Google Scholar
• Cannon LA, Simon DI, Kereiakes D et al. The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT small vessel trial. Catheter. Cardiovasc. Interv. 80(4), 546–553 (2012).
   PubMed Web of Science ®Google Scholar
• Claessen BE, Smits PC, Kereiakes DJ et al. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus-versus paclitaxel-eluting stents pooled analysis from the SPIRIT (clinical evaluation of the XIENCE V everolimus eluting coronary stent system) and COMPARE (second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) randomized trials. JACC Cardiovasc. Interv. 4(11), 1209–1215 (2011).
   PubMed Web of Science ®Google Scholar
• Nasu K, Oikawa Y, Shirai S et al. Two-year clinical outcome in patients with small coronary artery disease treated with everolimus-versus paclitaxel-eluting stenting. J. Cardiol. 68(3), 209–214 (2016).
   PubMed Web of Science ®Google Scholar
• Costa M, Kereiakes D, Smith R et al. TCT-608 two-year outcomes after implantation of XIENCE PRIME and XIENCE PRIME long lesion stents in patients with coronary artery disease: results of the SPIRIT PRIME multicenter pivotal clinical trial. J. Am. College Cardiol. 60(17), B176–B177 (2012).
   Google Scholar
• Diaz Fernandez JF, Camacho Freire SJ, Fernandez Guerrero JC et al. Everolimus drug-eluting stent performance in patients with long coronary lesions: the multicenter Longprime registry. Catheter. Cardiovasc. Interv. 92(7), E493–E501 (2018).
   PubMed Web of Science ®Google Scholar
• Bouras G, Jhamnani S, Ng VG et al. Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheter. Cardiovasc. Interv. 89(6), 984–991 (2017).
   PubMed Web of Science ®Google Scholar
• Gautier A, Hovasse T, Arroyo D et al. Safety and efficacy of 48 mm Xience Xpedition everolimus-eluting stent for the treatment of long coronary lesions. Catheter. Cardiovasc. Interv. 100(2), 179–187 (2022).
   PubMed Web of Science ®Google Scholar
• Tan CK, Tin ZL, Arshad MKM et al. Treatment with 48-mm everolimus-eluting stents: procedural safety and 12-month patient outcome. Herz 44(5), 419–424 (2019).
   PubMed Web of Science ®Google Scholar
• Senguttuvan NB, Kongara R, Sadhanandham S et al. Procedural safety and long-term clinical outcomes in patients receiving ultra-long everolimus-eluting stent: a single-center real-world experience. Cardiol. Res. 13(2), 104–109 (2022).
   PubMed Web of Science ®Google Scholar
• Kang D-Y, Lee CH, Lee PH et al. Comparison of Resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial. CoronaryArtery Dis. 30(1), 59–66 (2019).
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Kini AS, Karmpaliotis D et al. Safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization: results from the EXPERT CTO multicenter trial (Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occlusions). JACC Cardiovasc. Interv. 8(6), 761–769 (2015).
   PubMed Web of Science ®Google Scholar
• De la Torre Hernandez JM, Alfonso F, Sanchez Recalde A et al. Comparison of paclitaxel-eluting stents (Taxus) and everolimus-eluting stents (Xience) in left main coronary artery disease with 3 years follow-up (from the ESTROFA-LM registry). Am. J. Cardiol. 111(5), 676–683 (2013).
   PubMed Web of Science ®Google Scholar
• Mehilli J, Richardt G, Valgimigli M et al. Zotarolimus-versus everolimus-eluting stents for unprotected left main coronary artery disease. J. Am. College Cardiol. 62(22), 2075–2082 (2013).
   PubMed Web of Science ®Google Scholar
• Stone GW, Kappetein AP, Sabik JF et al. Five-year outcomes after PCI or CABG for left main coronary disease. N. Engl. J. Med. 381(19), 1820–1830 (2019).
   PubMed Web of Science ®Google Scholar
• Naidu SS, Krucoff MW, Rutledge DR et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. JACC Cardiovasc. Interv. 5(6), 626–635 (2012).
   PubMed Web of Science ®Google Scholar
• Hermiller JB, Applegate RJ, Baird C et al. Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: four-year results from the Xience V USA study. Catheter. Cardiovasc. Interv. 88(1), 62–70 (2016).
   PubMed Web of Science ®Google Scholar
• Abbott Vascular Inc. XIENCE V USA dual antiplatelet therapy (DAPT) cohort (XVU-AV DAPT) (2010). www.clinicaltrials.gov/ct2/show/NCT01106534
   Google Scholar
• Seth A, Patel TM, Stuteville M et al. Three-year data from the XIENCE V INDIA study: safety and efficacy of XIENCE V in 1000 real world Indian patients. Indian Heart J. 66(3), 302–308 (2014).
   PubMedGoogle Scholar
• Aoki J, Kozuma K, Awata M et al. Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES (XIENCE V/PROMUS) in Japan. Cardiovasc. Interv. Ther. 34(1), 40–46 (2019).
   PubMed Web of Science ®Google Scholar
• Runlin G. XIENCE V China RCT 2 year results. China Interventional Therapeutics (CIT). Shanghai, China (2014).
   Google Scholar
• Trabattoni D, Fabbiocchi F, Montorsi P et al. A long-term single-center registry of 6893 patients undergoing elective percutaneous coronary intervention with the Xience everolimus-eluting stent. J. Invasive Cardiol. 31(5), 146–151 (2019).
   PubMed Web of Science ®Google Scholar
• Abbott Vascular Inc. XIENCE Skypoint large vessel post approval study (SPIRIT XLV PAS) (2022). www.clinicaltrials.gov/ct2/show/NCT05423379
   Google Scholar
• Park S-J. Evaluation of effectiveness and safety of XIENCE Sierra in routine clinical practice (IRIS Sierra) [NCT03967158] (2019). www.clinicaltrials.gov/ct2/show/NCT03967158
   Google Scholar
• Park S-J. XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice (IRIS XPEDITION) [NCT02042300] (2014). https://clinicaltrials.gov/ct2/show/NCT02042300
   Google Scholar
• Lefevre T, Haude M, Neumann FJ et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II trial. JACC Cardiovasc. Interv. 11(10), 995–1002 (2018).
   PubMed Web of Science ®Google Scholar
• Ton S, Ralph T, Bernhard W et al. Sirolimus-eluting or everolimus-eluting stents for coronary artery disease: 5-year outcomes of the randomised BIOFLOW-IV trial. Euro Interv. 18(14), 1197–1200 (2023).
   Google Scholar
• Kandzari DE, Koolen JJ, Doros G et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: BIOFLOW V final 5-year outcomes. JACC Cardiovasc. Interv. 15(18), 1852–1860 (2022).
   PubMed Web of Science ®Google Scholar
• Pilgrim T, Piccolo R, Heg D et al. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet 392(10149), 737–746 (2018).
   PubMed Web of Science ®Google Scholar
• Pilgrim T, Muller O, Heg D et al. Biodegradable-versus durable-polymer drug-eluting stents for STEMI: final 2-year outcomes of the BIOSTEMI trial. Cardiovasc. Interv. 14(6), 639–648 (2021).
   PubMedGoogle Scholar
• Pilgrim T, Rothenbuhler M, Siontis GC et al. Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of individual patient data from 5 randomized trials. Am. Heart J. 235, 140–148 (2021).
   PubMed Web of Science ®Google Scholar
• Zivelonghi C, Agostoni P, Teeuwen K et al. 3-year clinical outcomes of the PRISON-IV trial: ultrathin struts versus conventional drug-eluting stents in total coronary occlusions. JACC Cardiovasc. Interv. 12(17), 1747–1749 (2019).
   PubMed Web of Science ®Google Scholar
• Yamaji K, Zanchin T, Zanchin C et al. Unselected use of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for coronary revascularization. Circ. Cardiovasc. Interv. 11(9), e006741 (2018).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kadota K, Nakagawa Y et al. Ultrathin, biodegradable-polymer sirolimus-eluting stent vs thin, durable-polymer everolimus-eluting stent. JACC Cardiovasc. Interv. 15(13), 1324–1334 (2022).
   PubMed Web of Science ®Google Scholar
• Lansky AJ, Kastrati A, Edelman ER et al. Comparison of the absorbable polymer sirolimus-eluting stent (MiStent) to the durable polymer everolimus-eluting stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 studies). Am. J. Cardiol. 117(4), 532–538 (2016).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Serruys PW, Kogame N et al. Final 3-year outcomes of MiStent biodegradable polymer crystalline sirolimus-eluting stent versus Xience permanent polymer everolimus-eluting stent: insights from the DESSOLVE III all-comers randomized trial. Circ. Cardiovasc. Interv. 13(6), e008737 (2020).
   PubMed Web of Science ®Google Scholar
• Wijns W, Valdes-Chavarri M, Richardt G et al. Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial. Euro Interv. 14(3), e343–e351 (2018).
   Google Scholar
• Azzalini L, Demir OM, Gasparini GL et al. Outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent in patients with chronic total occlusions: a multicenter registry. Int. J. Cardiol. 258, 36–41 (2018).
   PubMed Web of Science ®Google Scholar
• Alexandre AA, Sasko K, Elvin K et al. Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial. Euro Interven. 14(11), e1207–e1214 (2018).
   Google Scholar
• Robbert JdW, Azfar Z, Hironori H et al. Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial. Euro Interv. 18(6), 492–502 (2022).
   Google Scholar
• Lansky AJ, Kereiakes DJ, Baumbach A et al. Novel supreme drug-eluting stents with early synchronized antiproliferative drug delivery to inhibit smooth muscle cell proliferation after drug-eluting stents implantation in coronary artery disease: results of the PIONEER III randomized clinical trial. Circulation 143(22), 2143–2154 (2021).
   PubMed Web of Science ®Google Scholar
• Kirtane AJ, Doshi D, Leon MB et al. Treatment of higher-risk patients with an indication for revascularization: evolution within the field of contemporary percutaneous coronary intervention. Circulation 134(5), 422–431 (2016).
   PubMed Web of Science ®Google Scholar
• Bavishi C, Sardar P, Chatterjee S et al. Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: meta-analysis of randomized trials. Am. Heart J. 185, 26–34 (2017).
   PubMed Web of Science ®Google Scholar
• Räber L, Mintz GS, Koskinas KC et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Euro Interven. 14(6), 656–677 (2018).
   Google Scholar
• Capodanno D, Bhatt DL, Gibson CM et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat. Rev. Cardiol. 19(2), 117–132 (2022).
   PubMed Web of Science ®Google Scholar
• Runlin G, Bo X, Alexandra JL et al. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. Euro Interven. 9(1), 75–83 (2013).
   Google Scholar
• Xu B, Saito Y, Baumbach A et al. 2-year clinical outcomes of an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent compared with a durable-polymer everolimus-eluting stent. JACC Cardiovasc. Interv. 12(17), 1679–1687 (2019).
   PubMed Web of Science ®Google Scholar
• Collet JP, Thiele H, Barbato E et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 42(14), 1289–1367 (2021).
   PubMed Web of Science ®Google Scholar
• Chandiramani R, Spirito A, Johnson JW et al. Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. Expert Rev. Cardiovasc. Ther. 21(5), 311–328 (2023).
   PubMed Web of Science ®Google Scholar
• Natsuaki M, Morimoto T, Yamamoto E et al. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc. Interv. Ther. 31(3), 196–209 (2016).
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 321(24), 2414–2427 (2019).
   PubMed Web of Science ®Google Scholar
• Watanabe H, Morimoto T, Natsuaki M et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 7(4), 407–417 (2022).
   PubMed Web of Science ®Google Scholar
• Hahn JY, Song YB, Oh JH et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 391(10127), 1274–1284 (2018).
   PubMed Web of Science ®Google Scholar
• Choi KH, Park YH, Song YB et al. Long-term effects of P2Y12 inhibitor monotherapy after percutaneous coronary intervention: 3-year follow-up of the SMART-CHOICE randomized clinical trial. JAMA Cardiol. 7(11), 1100–1108 (2022).
   PubMed Web of Science ®Google Scholar
• George D, Usman B, Samin KS et al. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. Euro Interv. 17(16), 1330–1339 (2022).
   Google Scholar
• Valgimigli M, Cao D, Angiolillo DJ et al. Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI. J. Am. Coll. Cardiol. 78(21), 2060–2072 (2021).
   PubMed Web of Science ®Google Scholar
• Mehran R, Cao D, Angiolillo DJ et al. 3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation. JACC Cardiovasc. Interv. 14(17), 1870–1883 (2021).
   PubMed Web of Science ®Google Scholar
• Abbott Vascular Inc. XIENCE NANO everolimus eluting coronary stent system (2011). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P070015S054
   Google Scholar
• US Food & Drug Administration. Xience Prime and Xience Prime LL everolimus eluting coronary stent system (2011). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110019
   Google Scholar
• Abbott Vascular Inc. Xience Alpine RX & OTW everolimus eluting coronary stent system (2014). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110019S070
   Google Scholar
• Abbott Vascular Inc. Xience Xpedition, Xience Xpedition SV, and Xience Xpedition LL everolimus eluting coronary stent system (2012). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110019S025
   Google Scholar
• Abbott Vascular Inc. Xience Sierra everolimus eluting coronary stent system (2018). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110019S094
   Google Scholar
• Abbott Vascular Inc. Xience Skypoint everolimus eluting coronary stent system (2021). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110019S113
   Google Scholar
• Abbott Vascular Inc. Xience Prime everolimus eluting coronary stent system, Xience Xpedition everolimus eluting coronary stent system (2014). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110019S066
   Google Scholar
• Abbott Vascular Inc. Xience V and Nano everolimus eluting coronary stent system (2015). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P070015S128
   Google Scholar
• Abbott Vascular Inc. Xience Prime/LL, Xpedition, Xpedition SV,LL, and Alpine everolimus eluting coronary stent system (2015). www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110019S075
   Google Scholar
• Abbott Vascular Inc. Abbott announces CE mark and european launch of next-generation Xience Xpedition™ drug eluting stent (2012). https://abbott.mediaroom.com/2012-08-20-Abbott-Announces-CE-Mark-and-European-Launch-of-Next-Generation-XIENCE-Xpedition-Drug-Eluting-Stent
   Google Scholar
• Abbott Vascular Inc. Abbott introduces next generation of most widely used heart stent for people with coronary artery disease in Europe (2017). https://abbott.mediaroom.com/2017-10-30-Abbott-Introduces-Next-Generation-of-Most-Widely-Used-Heart-Stent-for-People-with-Coronary-Artery-Disease-in-Europe-1
   Google Scholar
• Abbott Vascular Inc. Abbott's Xience™ stent receives european approval for one-month dual anti-platelet therapy (DAPT) for high bleeding risk patients (2021). https://abbott.mediaroom.com/2021-04-06-Abbotts-XIENCE-TM-Stent-Receives-European-Approval-for-One-Month-Dual-Anti-Platelet-Therapy-DAPT-for-High-Bleeding-Risk-Patients
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. List of approved products – new & improved medical devices (2022). www.pmda.go.jp/english/review-services/reviews/approved-information/devices/0001.html
   Google Scholar
• Abbott Vascular Inc. Abbott's Xience stent receives FDA approval for shortest blood thinner course for high bleeding risk patients (2021). https://abbott.mediaroom.com/2021-06-30-Abbotts-XIENCE-Stent-Receives-FDA-Approval-for-Shortest-Blood-Thinner-Course-for-High-Bleeding-Risk-Patients
   Google Scholar